Gene editing has been a much sought after and controversial technology. Last month, part of the World Health Organization called for an international registry to track all research into editing the human genome. Purdue University researchers, including one who was inspired by the cancer dea ... more
Breakthrough discovery may make blood test feasible for detecting cancer
Doctors may soon be able to detect and monitor a patient’s cancer with a simple blood test, reducing or eliminating the need for more invasive procedures, according to Purdue University research.
W. Andy Tao, a professor of biochemistry and member of the Purdue University Center for Cancer Research and colleagues identified a series of proteins in blood plasma that, when elevated, signify that the patient has cancer.
Tao’s work was done with samples from breast cancer patients, but it is possible the method could work for any type of cancer and other types of diseases. The work relies on analysis of microvesicles and exosomes in blood plasma.
Protein phosphorylation, the addition of a phosphate group to a protein can lead to cancer cell formation. So phosphorylated proteins, known as phosphoproteins, have been seen as prime candidates for cancer biomarkers. Until now, however, scientists weren’t sure identification of phosphoproteins in blood was possible because the liver releases phosphatase into the bloodstream, which dephosphorylates proteins.
“There are so many types of cancer, even multiple forms for different types of cancer, that finding biomarkers has been discouraging,” Tao said. “This is definitely a breakthrough, showing the feasibility of using phosphoproteins in blood for detecting and monitoring diseases.”
Tao and his colleagues found nearly 2,400 phosphoproteins in a blood sample and identified 144 that were significantly elevated in cancer patients. The study compared 1-milliliter blood samples from 30 breast cancer patients with six healthy controls.
The researchers used centrifuges to separate plasma from red blood cells, and high-speed and ultra-high-speed centrifuges to further separate microvesicles and exosomes. Those particles, which are released from cells and enter the bloodstream, may play a role in intercellular communication and are thought to be involved in metastasis, spreading cancer from one place to another in the body. They also encapsulate phosphoproteins, which Tao’s team identified using mass spectrometry.
“Extracellular vesicles, which include exosomes and microvesicles, are membrane-encapsulated. They are stable, which is important,” Tao said. “The samples we used were 5 years old, and we were still able to identify phosphoproteins, suggesting this is a viable method for identifying disease biomarkers.”
A simple blood test for cancer would be far less invasive than scopes or biopsies that remove tissue. A doctor could also regularly test a cancer patient’s blood to understand the effectiveness of treatment and monitor patients after treatment to see if the cancer is returning.
“There is currently almost no way to monitor patients after treatment,” Tao said. “Doctors have to wait until cancer comes back.”
Timothy Ratliff, director of the Purdue University Center for Cancer Research, said the findings are promising for early detection of cancer.
“The vesicles and exosomes are present and released by all cancers, so it could be that there are general patterns for cancer tissues, but it’s more likely that Andy will develop patterns associated with different cancers. It’s really exciting,” Ratliff said. “Early detection in cancer is key and has been shown to clearly reduce the death rate associated with the disease.”
Tao plans to analyze increased levels of phosphoproteins in various types of cancer to determine whether there are patterns that would signify the type of cancer a patient has. His company, Tymora Analytical, is also developing technology that would allow doctors to insert blood samples onto a cartridge and analyze phosphoproteins present, eliminating the need for ultra-high-speed centrifuges that aren’t practical in clinical settings.
- Purdue University
- blood samples
- mass spectrometry
- high speed centrifuges
- extracellular vesicles
- cancer biomarkers
- breast cancer
- blood cells
Purdue University researchers have developed a technology aimed at making it easier to deliver cancer treatment to the right "address" in the body while also easing the painful side effects of chemotherapy on patients. One of the big issues with chemotherapy is that most treatment approache ... more
Purdue University researchers have developed a new flexible and translucent base for silicon nanoneedle patches to deliver exact doses of biomolecules directly into cells and expand observational opportunities."This means that eight or nine silicon nanoneedles can be injected into a single ... more
A new automated system detects cracks in the steel components of nuclear power plants and has been shown to be more accurate than other automated systems. more
- 1New Indication of a Link Between Alzheimer’s and Diabetes
- 2Click... Resistant bacteria caught in the act!
- 3The relationship of proteins
- 4Could the blood of COVID-19 patients be used to predict disease progression?
- 5Taking a deep look into animals
- 6Nanosafety research without animal experiments
- 7RNA structures by the thousands
- 8Start-up Raises 16.3 million Euros to Prepare Market Launch of its SARS-CoV-2 Rapid Testing System
- 9DKSH extends partnership with Bruker in China
- 10Snapshot of exploding oxygen